MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/10760296221103864

Медицинская библиотека · Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2022

Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study.

Al Harbi Shmeylan, Kensara Raed, Aljuhani Ohoud, Korayem Ghazwa B, Altebainawi Ali F, Al Harthi Abdullah, Vishwakarma Ramesh, Alenazi Alaa M, Almutairi Abdulmajed, Alshaya Omar, Alraddadi Sultan, Al Sulaiman Tareq, Aldakkan Latifah, Mahboob Reem, Alaamer Kholoud, Alissa Abdulrahman, Hafiz Awatif, Aldhayyan Nada, Althewaibi Sara, Alenezi Farhan, Alkhotani Nadeen Y, Alghamdi Sara A, Alenazi Abeer A, Al Sulaiman Khalid

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

PURPOSE: Coagulation abnormalities are one of the most important complications of severe COVID-19, which might lead to venous thromboembolism (VTE). Hypercoagulability with hyperfibrinogenemia causes large vessel thrombosis and major thromboembolic sequelae. Statins are potentially a potent adjuvant therapy in COVID-19 infection due to their pleiotropic effect. This study aims to evaluate the effectiveness of statins in reducing the risk of thrombosis among hospitalized critically ill patients with COVID-19.

METHODS

A multicenter, retrospective cohort study of all critically ill adult patients with confirmed COVID-19 admitted to Intensive Care Units (ICUs) between March 1, 2020, and March 31, 2021. Eligible patients were categorized based on their usage of statins throughout their ICU stay and were matched with a propensity score. The primary endpoint was the odds of all cases of thrombosis; other outcomes were considered secondary.

RESULTS

A total of 1039 patients were eligible; following propensity score matching, 396 patients were included (1:1 ratio). The odds of all thrombosis cases and VTE events did not differ significantly between the two groups (OR 0.84 (95% CI 0.43, 1.66), P = 0.62 and OR 1.13 (95% CI 0.43, 2.98), P = 0.81, respectively. On multivariable Cox proportional hazards regression analysis, patients who received statin therapy had lower 30-day (HR 0.72 (95 % CI 0.54, 0.97), P = 0.03) and in-hospital mortality (HR 0.67 (95 % CI 0.51, 0.89), P = 0.007). Other secondary outcomes were not statistically significant between the two groups except for D-dimer levels (peak) during ICU stay.

CONCLUSION

The use of statin therapy during ICU stay was not associated with thrombosis reduction in critically ill patients with COVID-19; however, it has been associated with survival benefits.

Для цитирования: Al Harbi Shmeylan, Kensara Raed, Aljuhani Ohoud, Korayem Ghazwa B, Altebainawi Ali F, Al Harthi Abdullah, Vishwakarma Ramesh, Alenazi Alaa M, Almutairi Abdulmajed, Alshaya Omar, Alraddadi Sultan, Al Sulaiman Tareq, Aldakkan Latifah, Mahboob Reem, Alaamer Kholoud, Alissa Abdulrahman, Hafiz Awatif, Aldhayyan Nada, Althewaibi Sara, Alenezi Farhan, Alkhotani Nadeen Y, Alghamdi Sara A, Alenazi Abeer A, Al Sulaiman Khalid. Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study.. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2022. DOI: 10.1177/10760296221103864.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.